Bexion Pharmaceuticals’ Early-Stage Cancer Drug, BXQ-350 Hailed as Game Changer For the Treatment of solid tumors and gliomas
Bexion Pharmaceuticals’ investigational cancer treatment, BXQ-350, is receiving lots of mainstream media coverage as a potential game-changer.
BXQ-350 is a formulation of a synthetically produced, human lysosomal protein, Saposin C (sphingolipid activator protein, or SapC), and the phospholipid dioleoylphosphatidylserine (DOPS). It is being developed as a first-in-class treatment for solid tumors and gliomas.
In animal models, the effect of BXQ-350 has been significant. Earlier this year at the American Society for Clinical Oncology, Be...
